Evidence map›Paper›PMID 29789781›Full record

ArticleBioMed research international2018

Serum Cystatin C Level Is Not a Promising Biomarker for Predicting Clinicopathological Characteristics of Bladder Urothelial Tumors.

Hui Wang, Lijian Gao, Cuiyu Meng, Nengwang Yu, Feilong Yang, Cong Zhang, Dawei Li, Lei Yan, Hainan Liu, Zhonghua Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Role of cystatin C in urogenital malignancy.Frontiers in endocrinology · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hui WangDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250012, China.ORCID 0000-0003-3816-3182
Lijian GaoDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250012, China.
Cuiyu MengDepartment of ICU, Dezhou People's Hospital, Dezhou, Shandong Province 253000, China.
Nengwang YuDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250012, China.
Feilong YangDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250012, China.
Cong ZhangDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250012, China.
Dawei LiDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250012, China.ORCID 0000-0001-5939-4110
Lei YanDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250012, China.
Hainan LiuDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250012, China.
Zhonghua XuDepartment of Urology, Qilu Hospital of Shandong University, Jinan 250012, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of cystatin C (Cys-C) in tumorigenesis and progression of bladder urothelial tumors (BUT) is still indefinite. We retrospectively collected the clinical information from the records of 425 BUT patients. Pretreatment serum Cys-C levels were compared across the various groups. Then we subgroup the patients with GFR ≥ 90 mg/min/1.73 m

Indexed as

Urinary Bladder NeoplasmsAgedBiomarkersCystatin CFemaleHumansMaleMiddle AgedRetrospective StudiesUrinary BladderBiomarkersCystatin C

Identifiers

PMID29789781
PMCPMC5896344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.